Sealbond Ltd - 26 Oct 2026 Form 4 Insider Report for Dogwood Therapeutics, Inc. (DWTX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
27 Oct 2026, 16:05:27 UTC
Prior SEC filing
25 Nov 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Wong Wun Lam, Director of Sealbond Limited
Filing notes and source

Key filing fact

Sealbond Ltd filed Form 4 for Dogwood Therapeutics, Inc. (DWTX) on 27 Oct 2026.

Key facts

  • This page summarizes Sealbond Ltd's Form 4 filing for Dogwood Therapeutics, Inc. (DWTX).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 27 Oct 2026, 16:05.

Change

  • Previous filing in this sequence was filed on 25 Nov 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0002040446 Primary reporting owner

Sealbond Ltd

Relationship
Director, Other*, 10%+ Owner
Address
2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG
Signature
/s/ Wong Wun Lam, Director of Sealbond Limited
Signature date
27 Oct 2026
CIK 0002061651

Conjoint Inc.

Relationship
Director, Other*, 10%+ Owner
Address
2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG
Signature
/s/ Yu Ying Choi Alan Abel, Director of Conjoint Inc.
Signature date
27 Oct 2026
CIK 0001297567

CK Life Sciences Intl (Holdings) Inc

Relationship
Director, Other*, 10%+ Owner
Address
2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG
Signature
/s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc.
Signature date
27 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DWTX transaction

Common Stock

Award

Transaction value
Shares
+4,098,360
Change %
+19%
Price
$1.22*
Shares after
25,920,693
Date
26 Oct 2026
Ownership
Direct
Footnotes
F1, F2
DWTX transaction

Common Stock

Award

Transaction value
Shares
+4,098,360
Change %
+19%
Price
$1.22*
Shares after
25,920,693
Date
26 Oct 2026
Ownership
Direct
Footnotes
F1, F2
DWTX transaction

Common Stock

Award

Transaction value
Shares
+4,098,360
Change %
+19%
Price
$1.22*
Shares after
25,920,693
Date
26 Oct 2026
Ownership
Direct
Footnotes
F1, F2
DWTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,842,638
Date
26 Oct 2026
Ownership
By Conjoint Inc.
Footnotes
F3
DWTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,842,638
Date
26 Oct 2026
Ownership
By Conjoint Inc.
Footnotes
F3
DWTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
2,842,638
Date
26 Oct 2026
Ownership
By Conjoint Inc.
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares acquired in a private placement pursuant to a Subscription Agreement dated October 19, 2026 by and between the Issuer and Sealbond Limited.

Footnote F2

Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F3

Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

SEC remarks

Mr. Yu Ying Choi Alan Abel ("Mr. Yu"), the Deputy Chairman of CKLS, and Dr. Toh Kean Meng Melvin ("Dr. Toh"), the Vice President and Chief Scientific Officer and Executive Director of CKLS, have been appointed to the board of directors of the Issuer, and each of Mr. Yu and Dr. Toh have been deputized to represent the Reporting Person on the board of directors. By virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Mr. Yu and Dr. Toh have filed separate Section 16 reports disclosing securities of the Issuer that each may respectively be deemed to beneficially own for Section 16 purposes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .